Get the Stockscreener App
13.41
3.47%
0.45
Kalvista Pharmaceuticals Inc stock is traded at $13.41, with a volume of 590.12K.
It is up +3.47% in the last 24 hours and down -15.18% over the past month.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.
See More
Previous Close:
$12.96
Open:
$13.12
24h Volume:
590.12K
Relative Volume:
0.51
Market Cap:
$669.88M
Revenue:
-
Net Income/Loss:
$-156.39M
P/E Ratio:
-3.6341
EPS:
-3.69
Net Cash Flow:
$-123.06M
1W Performance:
+4.11%
1M Performance:
-15.18%
6M Performance:
+33.70%
1Y Performance:
+7.97%
1-Day Range:
$12.87
$13.53
1-Week Range:
$12.30
$13.53
52-Week Range:
$7.30
$16.32
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
Name
Kalvista Pharmaceuticals Inc
Sector
Industry
Phone
(857) 999-0075
Address
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Compare KALV with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
13.41 | 666.38M | 0 | -156.39M | -123.06M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-31-25 | Initiated | JMP Securities | Mkt Outperform |
| Jan-07-25 | Initiated | TD Cowen | Buy |
| Dec-18-24 | Initiated | BofA Securities | Buy |
| Jun-15-20 | Initiated | H.C. Wainwright | Buy |
| Jul-29-19 | Initiated | SVB Leerink | Outperform |
| Mar-20-19 | Initiated | Needham | Buy |
| Oct-30-18 | Initiated | Jefferies | Buy |
| Sep-21-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-31-17 | Initiated | BTIG Research | Buy |
View All
Kalvista Pharmaceuticals Inc Stock (KALV) Latest News
Momentum Traders Eye KalVista Pharmaceuticals Inc. for Quick BounceEarnings Overview Report & Expert Approved Trade Ideas - beatles.ru
Yea Christopher, KalVista Pharmaceuticals chief development officer, sells $34k in stock - Investing.com
Kalvista pharma CMO Audhya sells $38k in shares - Investing.com
Can KalVista Pharmaceuticals Inc. maintain sales growthJuly 2025 Catalysts & Reliable Trade Execution Plans - thegnnews.com
How institutional ownership impacts KalVista Pharmaceuticals Inc. stockJuly 2025 Highlights & Community Supported Trade Ideas - Newser
KalVista Pharmaceuticals Inc. stock trend outlook and recovery path2025 Volume Leaders & Technical Analysis for Trade Confirmation - Newser
Will KalVista Pharmaceuticals Inc. benefit from macro trendsWeekly Stock Report & AI Enhanced Trade Execution Alerts - Newser
Does KalVista Pharmaceuticals Inc. qualify in momentum factor screening2025 Bull vs Bear & AI Powered Buy and Sell Recommendations - Newser
Can swing trading help recover from KalVista Pharmaceuticals Inc. lossesBuy Signal & Momentum Based Trading Signals - Newser
Is KalVista Pharmaceuticals Inc. meeting your algorithmic filter criteriaEarnings Overview Report & Accurate Technical Buy Alerts - Newser
Applying Wyckoff theory to KalVista Pharmaceuticals Inc. stockJuly 2025 Short Interest & AI Optimized Trading Strategy Guides - Newser
KalVista eyes growth as analysts point to $651M in peak orphan drug sales - S&P Global
Intraday pattern recognizer results for KalVista Pharmaceuticals Inc.July 2025 EndofMonth & Fast Entry High Yield Stock Tips - Newser
Measuring KalVista Pharmaceuticals Inc.’s beta against major indices2025 Earnings Surprises & Entry Point Strategy Guides - Newser
What makes KalVista Pharmaceuticals Inc. stock price move sharplyAnalyst Downgrade & Risk Adjusted Buy/Sell Alerts - sundaytimes.kr
Regulatory Risk and Reward: Navigating FDA Delays in the ALS Therapeutics Landscape - AInvest
KalVista Pharmaceuticals Announces Maintenance of Orphan Designation for Sebetralstat in European Union - BioSpace
KalVista Pharmaceuticals Announces Maintenance of Orphan Designa - GuruFocus
How to integrate KalVista Pharmaceuticals Inc. into portfolio analysis toolsFree Market Entry and Exit Point Tips - Newser
FDA approved six NMEs in July - BioCentury
KalVista Pharmaceuticals Grants Stock Options to New Hires - AInvest
KalVista Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(4) - MarketScreener
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 4, 2025 - BioSpace
Reversal Traders Monitor KalVista Pharmaceuticals Inc. for EntryFundamental Growth Stock Analysis Shows Strength - metal.it
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | KALV Stock News - GuruFocus
Published on: 2025-08-04 07:21:19 - Jammu Links News
What are analysts’ price targets for KalVista Pharmaceuticals Inc. in the next 12 monthsBuild wealth steadily with proven stock picks - Jammu Links News
What institutional investors are buying KalVista Pharmaceuticals Inc. stockRapid wealth creation - Jammu Links News
Is KalVista Pharmaceuticals Inc. stock overvalued or undervaluedMaximize your portfolio’s earning power - Jammu Links News
What analysts say about KalVista Pharmaceuticals Inc. stockInvest confidently with actionable market data - Jammu Links News
What are the technical indicators suggesting about KalVista Pharmaceuticals Inc.Unstoppable investment returns - Jammu Links News
When is KalVista Pharmaceuticals Inc. stock expected to show significant growthAchieve consistent profits with expert strategies - Jammu Links News
What drives KalVista Pharmaceuticals Inc. stock priceConsistently profitable trades - Jammu Links News
KalVista Pharmaceuticals Inc. Stock Analysis and ForecastUnlock exclusive investment alerts - Jammu Links News
What is the risk reward ratio of investing in KalVista Pharmaceuticals Inc. stockAdvanced Screener Growth Plan For Every Investor - Jammu Links News
What are KalVista Pharmaceuticals Inc. company’s key revenue driversAI Powered Tracker That Work - Jammu Links News
Does KalVista Pharmaceuticals Inc. stock pay reliable dividendsPredictable Income Summary for Long-Term Trades - Newser
KalVista Pharmaceuticals (KALV) Received Positive Opinion From the European Medicines Agency - MSN
Published on: 2025-07-29 19:52:44 - metal.it
Sebetralstat recommended for EU approval for treating HAE attacks - Angioedema News
What is the dividend policy of KalVista Pharmaceuticals Inc. stockBreakthrough investment results - jammulinksnews.com
KalVista Pharmaceuticals Faces Downgrade Due to Shrinking Market and Oral Competitor Threat - AInvest
KalVista Pharmaceuticals Ekterly Faces A Shrinking Market And Oral Competitor Threat (Downgrade) - Seeking Alpha
Kalvista Pharmaceuticals shares rise 1.17% after-hours following positive CHMP opinion for sebetralstat. - AInvest
EMA’s CHMP adopts five orphans - BioCentury
What analysts say about KalVista Pharmaceuticals Inc. stock outlookPhenomenal capital gains - Jammu Links News
New medicines recommended for approval by EMA’s CHMP - The Pharma Letter
KalVista receives CHMP opinion recommending sebetralstat marketing authorization - TipRanks
KalVista, Biogen, Ionis get EU positive opinions for key drugs (KALV:NASDAQ) - Seeking Alpha
Kalvista Pharmaceuticals Inc Stock (KALV) Financials Data
Revenue
Net Income
Cash Flow
EPS
Kalvista Pharmaceuticals Inc Stock (KALV) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Audhya Paul K. | CHIEF MEDICAL OFFICER |
Aug 18 '25 |
Sale |
13.19 |
2,939 |
38,757 |
116,533 |
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER |
Aug 18 '25 |
Sale |
13.19 |
4,409 |
58,141 |
374,548 |
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER |
Jul 09 '25 |
Sale |
15.69 |
32,979 |
517,523 |
369,595 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER |
Jul 09 '25 |
Sale |
15.69 |
30,250 |
474,698 |
127,939 |
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER |
Jun 09 '25 |
Sale |
14.50 |
7,169 |
103,950 |
315,074 |
| Audhya Paul K. | CHIEF MEDICAL OFFICER |
May 23 '25 |
Sale |
11.31 |
2,146 |
24,272 |
113,026 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER |
May 23 '25 |
Sale |
11.31 |
1,926 |
21,782 |
98,189 |
| Audhya Paul K. | CHIEF MEDICAL OFFICER |
May 22 '25 |
Sale |
11.88 |
2,689 |
31,933 |
110,172 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER |
May 22 '25 |
Sale |
11.88 |
2,317 |
27,516 |
96,990 |
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER |
May 22 '25 |
Sale |
11.88 |
9,999 |
118,743 |
306,618 |
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):